A

한국유니온제약

080720KOSDAQ의약품 제조업

70.3 / 100

Reference Date: 2026-06-10

Financial Score26.5 / 40
News Sentiment18.8 / 25
Momentum10.0 / 20
Disclosure15.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Union Pharmaceutical focuses on manufacturing and selling specialty pharmaceuticals, exporting finished drugs, and providing CMO (contract manufacturing) services. The company specializes in antibiotics, cardiovascular, and musculoskeletal products, leveraging its GMP facilities and R&D efforts to enhance profitability. It has expanded exports to regions such as the Middle East, Southeast Asia, and South America, and is further expanding its CMO business and product portfolio through a newly completed factory.

Number of Employees

123people

Average Salary

39.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 11.934.0Point
PBR
Industry Average 0.893.5Point
ROE
419.43Industry Average 4.017.0Point

104.6x industry avg (excellent)

Debt Ratio
-21.02Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼23.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼92.6% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 88.4% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 75

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 2,725Won52-week high 2,72552-week low 2,725
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

20 totalPositive 6Neutral 13Negative 1
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-06-09
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-06-09
  • Neutral[기재정정]주요사항보고서(감자결정)2026-06-09
  • Neutral주주총회소집결의 (임시주주총회)2026-06-08
  • Neutral주주총회소집공고2026-06-08